New drug combo aims to stop prostate Cancer's return

NCT ID NCT05826509

Summary

This study is testing whether adding a medication called darolutamide to standard prostate cancer surgery works better than surgery alone for men with high-risk or locally advanced prostate cancer. About 240 participants will be randomly assigned to receive either just surgery or surgery plus darolutamide taken around the time of the operation. The main goal is to see if the drug combination helps keep the cancer from progressing to an incurable stage for longer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • CHU Bordeaux

    Bordeaux, France

  • CHU Grenoble

    Grenoble, France

  • CHU Lyon - Hôpital Edouard Herriot

    Lyon, France

  • CHU Lyon - Sud

    Pierre-Bénite, France

  • CHU Rennes

    Rennes, France

  • CHU Toulouse

    Toulouse, France

  • Chu Angers

    Angers, France

  • Chu Henri Mondor

    Créteil, France

  • Chu Tours - Hopital Bretonneau

    Tours, France

  • Clinique La Croix Du Sud

    Quint-Fonsegrives, France

  • Hopital Bichat - Ap-Hp

    Paris, 75018, France

  • Hopital Claude Huriez

    Lille, France

  • Hopital Europeen Georges-Pompidou

    Paris, France

  • Hopital Foch

    Suresnes, France

  • Hopital Paris Saint-Joseph

    Paris, 75014, France

  • Hopital Pitie Salpetriere

    Paris, France

  • Institut Bergonié

    Bordeaux, France

  • Institut Mutualiste Montsouris

    Paris, France

  • Institut Paoli-Calmettes

    Marseille, France

  • Institut Universitaire Du Cancer Toulouse - Oncopole

    Toulouse, France

Conditions

Explore the condition pages connected to this study.